Table 3.

Mean percent change from lead-in study baseline at 6-mo intervals for PTH, Ca×P, Ca, and P levels

WeekPTHCa × PCaP
Original cinacalcet mean (SE) [n]Original placebo mean (SE) [n]Original cinacalcet mean (SE) [n]Original placebo mean (SE) [n]Original cinacalcet mean (SE) [n]Original placebo mean (SE) [n]Original cinacalcet mean (SE) [n]Original placebo mean (SE) [n]
Week 26−51.2 (2.1) [318]9.9 (2.8) [246]−14.3 (1.7) [311]2.1 (1.8) [242]−5.9 (0.6) [316]1.3 (0.4) [246]−9.0 (1.7) [312]1.0 (1.8) [242]
Week 54−38.2 (2.9) [279]−12.3 (4.8) [200]−10.1 (2.0) [273]−10.3 (2.2) [196]−4.6 (0.6) [275]−5.5 (0.8) [201]−6.1 (1.8) [274]−5.0 (2.1) [197]
Week 84−28.8 (4.6) [222]−25.5 (5.2) [155]−11.1 (2.5) [221]−12.3 (2.5) [153]−6.1 (0.8) [225]−5.2 (0.8) [159]−6.0 (2.2) [221]−7.9 (2.3) [153]
Week 108−32.7 (4.4) [177]−25.8 (6.5) [123]−12.3 (2.2) [179]−13.0 (2.6) [124]−6.0 (0.9) [185]−3.7 (0.8) [131]−6.7 (2.1) [179]−10.4 (2.5) [124]
Week 132−35.0 (5.7) [110]−38.4 (5.7) [83]−7.7 (3.2) [112]−20.1 (2.9) [82]−5.3 (1.0) [116]−4.0 (1.2) [84]−4.1 (3.0) [113]−16.0 (3.0) [83]
Week 156−32.8 (9.0) [50]−24.0 (11.3) [29]−12.2 (4.7) [54]−14.6 (4.4) [34]−5.9 (1.3) [56]−4.0 (1.7) [35]−7.7 (4.5) [54]−9.8 (5.2) [34]
Week 180−49.7 (38.8) [2]−55.9 (35.3) [2]−9.6 (9.5) [9]−17.8 (10.9) [8]−5.7 (3.5) [10]0.4 (2.9) [8]−1.2 (13.5) [9]−19.7 (10.7) [9]